Bristol-Myers Squibb Co
Change company Symbol lookup
Select an option...
BMY Bristol-Myers Squibb Co
HBI HanesBrands Inc
BAC Bank of America Corp
RYB RYB Education Inc
RETA Reata Pharmaceuticals Inc
RDFN Redfin Corp
RCUS Arcus Biosciences Inc
RBWNY Koninklijke Boskalis Westminster NV
RBII Rising Biosciences Inc
RAD Rite Aid Corp
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Closing Price
$59.72
Day's Change
-0.09 (-0.15%)
Bid
--
Ask
--
B/A Size
--
Day's High
60.47
Day's Low
59.38
Volume
(Heavy Day)
Volume:
27,225,416

10-day average volume:
18,299,662
27,225,416

Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Valuation Ratios

Price/Earnings (TTM)
73.82x
Price/Sales (TTM)
4.36x
Price/Book (MRQ)
2.71x
Price/Cash Flow (TTM)
26.61x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

May 2020
Current Month
34.4M
Previous Month
31.9M
Percent of Float
1.52%
Days to Cover
2.3155 Days

Share Information

BMY is in a share class of common stock
Float
2.3B
Shares Outstanding
2.3B
Institutions Holding Shares
2,705
74.66%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Giovanni CaforioChmn.
  • David V. ElkinsCFO
  • Ann Powell Judge
  • Sandra LeungExec.VP
  • John E. ElickerExec.VP

Address

  • 430 E 29Th St Fl 14
  • New York, NY 10016-8367
  • Phone: (212) 546-4000
  • Fax: (302) 655-5049
  • https://www.bms.com/

Insider Trading

During the most recent quarter, 130K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.